GLP-1s as inflammatory modulators for many diseases
The host presented the concept that GLP-1 drugs act as inflammatory modulators throughout the body, which is why they are being studied for a wide range of conditions beyond obesity and diabetes.
Sign in to read the full idea
The argument, what validates it, the risks discussed and hearing it from the source are for signed-in members. Free accounts read 3 ideas in full a day. No card required.
The story so far
CONTESTED · 17 MENTIONS · 9 EPISODES · 6 SHOWS
22 JUL 2026 — 5 AUG 2026 · YESTERDAY
16 SUPPORT · 1 CHALLENGE
- MOTLEY FOOL MONEY
- THE TIM FERRISS SHOW
- BARRON'S STREETWISE · 9 MENTIONS
- Two-tiered GLP-1 market post-generics
- Lilly's underappreciated TAM and pipeline
- GLP-1s as inflammatory modulators for many diseases · THIS IDEA
- Next-gen Lilly drugs: retatrutide and orforglipron
- GLP-1 market in early to middle innings
- Lilly's injectable advantage over Novo
- Lilly's scale advantage in oral pill rollout
- Monthly injection as a future maintenance option
- Patent cliff risk appears manageable
- MOTLEY FOOL MONEY
- CNBC FAST MONEY
- CNBC FAST MONEY
- ANIMAL SPIRITS
- WSJ WHAT'S NEWS
- CNBC FAST MONEY
HOW THE SHOWS HAVE DISCUSSED THIS THESIS OVER TIME · NOT A PERFORMANCE RECORD